SCHEMBL3077856

SCHEMBL3077856

CS(=O)(=O)N(Cc1ccc2c(c1)[nH]c(=O)c1cccn12)C1CC1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 2/20 0.84
PLK4 O00444 2/20 0.84
MAPK13 O15264 2/20 0.84
PDPK1 O15530 2/20 0.84
DYRK3 O43781 2/20 0.84
ERBB2 P04626 2/20 0.84
PRKCG P05129 2/20 0.84
ROS1 P08922 2/20 0.84
KIT P10721 2/20 0.84
SRC P12931 2/20 0.84
PHKG2 P15735 2/20 0.84
AKT1 P31749 2/20 0.84
AKT2 P31751 2/20 0.84
MATK P42679 2/20 0.84
MAPKAPK2 P49137 2/20 0.84
BLK P51451 2/20 0.84
IRAK1 P51617 2/20 0.84
NEK4 P51957 2/20 0.84
PLK1 P53350 2/20 0.84
MAPK12 P53778 2/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3082011 0.92 CDC7 (1.00) CDC7PLK4MAPK13PDPK1DYRK3
SCHEMBL3075215 0.79 CDC7 (0.78) CDC7PLK4MAPK13PDPK1DYRK3
SCHEMBL3076285 0.78 PARP1 (0.56) CDC7PLK4MAPK13PDPK1DYRK3
SCHEMBL3062532 0.77 PARP1 (0.84) CDC7PLK4MAPK13PDPK1DYRK3
SCHEMBL3072167 0.73 PARP1 (1.00) CDC7PLK4MAPK13PDPK1DYRK3
SCHEMBL30273141 0.72 PARP1 (0.66) CDC7PLK4MAPK13PDPK1DYRK3
SCHEMBL29966010 0.72 PARP1 (0.66) CDC7PLK4MAPK13PDPK1DYRK3
SCHEMBL29892905 0.71 TP53 (0.61) CDC7PLK4MAPK13PDPK1DYRK3
SCHEMBL3077313 0.71 PARP1 (0.91) CDC7PLK4MAPK13PDPK1DYRK3
SCHEMBL3081256 0.71 PARP1 (0.91) CDC7PLK4MAPK13PDPK1DYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114948-B1 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE ABBVIE INC (US) 2014-06-25 EP disclosed
US-7790721-B2 Pyrroloquinoxalinone inhibitors of poly(ADP-ribose)polymerase ABBOTT LABORATORIES (US) 2010-09-07 US disclosed
EP-2114948-A2 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE Abbott Laboratories (US) 2009-11-11 EP disclosed
WO-2008082887-A2 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE ABBOTT LABORATORIES (US) 2008-07-10 WO disclosed
US-20080161292-A1 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE ABBOTT LABORATORIES (US) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161292-A1 INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE PARP1, PARP2, PARP3 CDC7 1235/4885PLK4 3279/4885MAPK13 4357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.